Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 29 от 154

Набира участници Фаза 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NSCLC (Non-small Cell Lung Cancer) Non-Small Cell Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma) +1

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Начало: 06.05.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Belgium, France +16 Revolution Medicines, Inc. NCT06881784

Набира участници Фаза 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Начало: 06.05.2025 Край: 14.03.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +16 AstraZeneca NCT06921785

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Myeloma Leukemia Non Hodgkin's Lymphoma

This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.

Начало: 06.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202091

Набира участници Фаза 1/2

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Advanced Solid Tumours

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.

Начало: 06.05.2025 Край: 01.02.2028 Възраст: от 18 г. Лечение

Australia, China LaNova Medicines Limited NCT06868199

Набира участници

CorWave LVAS FIH Study

Advanced Heart Failure

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.

Начало: 06.05.2025 Край: 01.05.2028 Възраст: 18–75 г. Лечение

Australia CorWave NCT06907017

Набира участници Фаза 3

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Myelodysplastic Syndromes

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Начало: 06.05.2025 Край: 01.05.2032 Възраст: от 18 г. Лечение

Australia, Brazil, Bulgaria +22 Takeda NCT06499285

Набира участници Фаза 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Начало: 05.05.2025 Край: 01.08.2027 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +9 Mediar Therapeutics NCT06967805

Набира участници Фаза 2

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Chronic Lymphocytic Leukemia

This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.

Начало: 05.05.2025 Край: 01.05.2031 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT06812715

Набира участници Фаза 1/2

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Начало: 02.05.2025 Край: 01.06.2031 Възраст: от 18 г. Лечение

Australia, China, Taiwan +3 BioNTech SE NCT06892548

Набира участници Фаза 1

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Psoriasis

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Начало: 02.05.2025 Край: 28.02.2027 Възраст: 18–65 г. Лечение

New Zealand, United States Jiangsu Hansoh Pharmaceutical Co., Ltd. NCT06846710

Набира участници Фаза 1

Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients

Moderate-to-severe Atopic Dermatitis

This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be increased or decreased in Part 1 or Part 2. Part 1 (SAD): Healthy participants receiving single doses of TRB-061 or placebo. Part 2 (MAD): Healthy participants receiving multiple doses (3 doses over 8 weeks) of TRB-061 or placebo. Part 3 (Phase 1b): Participants with moderate-to-severe AD receiving repeated doses (4 doses over 12 weeks) of TRB-061 or placebo.

Начало: 02.05.2025 Край: 29.02.2028 Възраст: 18–70 г. Лечение

Australia, New Zealand TRex Bio, Inc. NCT06934252

Набира участници

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis Interstitial Lung Disease

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.

Начало: 01.05.2025 Край: 01.12.2029 Възраст: 18–80 г.

Australia, Canada, Ireland +2 University of Massachusetts, Worcester NCT06855329

Набира участници

SPYRAL GEMINI Pilot Study

Hypertension Vascular Diseases Cardiovascular Diseases Chronic Kidney Diseases +1

The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.

Начало: 01.05.2025 Край: 22.12.2029 Възраст: 18–80 г. Лечение

Australia, Greece, Ireland +2 Medtronic Vascular NCT06907147

Набира участници

Evaluation of a Residential In-Reach Program in Regional and Rural Australia

Aged Acute Disease

Residential In-Reach (RIR) programs are designed to provide responsive care for residents in residential aged care homes (RACH) with the aim of avoiding unnecessary hospital transfers. The evidence for their clinical and cost-effectiveness and implementation has been established in urban settings, but there is a small amount of low-quality evidence for rural and regional settings. The Grampians Region Health Service Partnership Resi-In-Reach Redesign Committee will be implementing a new RIR program to be offered to all RACHs in the Grampians region, this project aims to evaluate the clinical and cost-effectiveness of this program, and its implementation in the rural and regional setting. A stepped-wedge trial will be conducted so that as the RIR program is gradually rolled-out across the region, outcomes can be compared in the same facilities across time and between different facilities. The primary outcome measure will be presentation to emergency departments and urgent care centres, and data will also be collected on other clinical outcomes and barriers and enablers of implementing the program. It is anticipated that there will be a reduction in hospital presentations, and a range of barriers and enablers unique to the rural and regional setting will emerge.

Начало: 01.05.2025 Край: 30.06.2026 Възраст: от 65 г. Здравни услуги

Australia Monash University NCT06901167

Набира участници Фаза 2

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Macular Edema

This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.

Начало: 01.05.2025 Край: 01.12.2026 Възраст: 18–85 г. Лечение

Australia Kiora Pharmaceuticals, Inc. NCT06825702

Набира участници Фаза 1/2

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Triple Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).

Начало: 30.04.2025 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, South Korea, United States Gilead Sciences NCT06926920

Набира участници Фаза 1/2

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Начало: 30.04.2025 Край: 01.12.2028 Възраст: 18–89 г. Лечение

Australia, China, United States Eikon Therapeutics NCT06907043

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Myeloma Non Hodgkin's Lymphoma Leukemia

Начало: 28.04.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202065

Набира участници Фаза 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 24.04.2025 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, Brazil, Czechia +8 AbbVie NCT06820463

Набира участници Фаза 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Carcinoma, Non-Small-Cell Lung

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Начало: 24.04.2025 Край: 30.04.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +30 Mirati Therapeutics Inc. NCT06875310

1 … 27 28 29 30 31 … 154